About The Article: This Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA ...

1. The use of glucagon-like peptide 1 (GLP-1) receptor agonists in adults with type 2 diabetes mellitus (T2DM) was not associated with increased risks of pulmonary aspiration during upper ...

aNottingham Digestive Diseases Centre (NDDC), Translational Medical Sciences, School of Medicine, University of Nottingham, NG7 2UH, UK bNIHR Nottingham Biomedical Research Centre, Nottingham ...

1. The use of glucagon-like peptide 1 (GLP-1) agonists in patients with inflammatory bowel disease (IBD) was associated with few episodes of disease exacerbation and resulted in a significant decrease ...

Background: Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have shown efficacy for reducing cardiovascular morbidity and mortality in patients with diabetes mellitus (DM), but conflicting ...

Glucagon-like peptide-1 (GLP-1) receptor agonists, which can slow gastric emptying and increase the risk of retained gastric contents, are increasingly prescribed for ...

USA: A recent narrative review published in Fertility and Sterility highlights the importance of comprehensive care for ...

Introduction: No interventions decrease the risk of developing pulmonary hypertension (PH). We hypothesize Glucagon-like peptide-1 receptor agonists (GLP-1) reduce risk of PH through salutary changes ...

Department of Anesthesiology and Pain Medicine, University of Ottawa, Ottawa, ON, Canada ...

Ozempic is one of several medications, called glucagon-like peptide-1 receptor agonists or GLP-1 RAs, that are prescribed to treat diabetes, obesity, and other weight-related medical conditions. A new ...

Ozempic breasts refer to changes in breast size or shape due to weight loss from GLP-1 drugs. Here’s how and why this side ...